Skip to main content
Evidence Snapshot

5-hydroxytryptamine receptor 6

CHEMBL3371 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:07Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3371
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 6 as ChEMBL target CHEMBL3371, mapped to UniProt P50406. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5-hydroxytryptamine receptor 6
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3371
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P50406
5-hydroxytryptamine receptor 6
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why 5-hydroxytryptamine receptor 6 matters

As of 2026-09-14

5-hydroxytryptamine receptor 6 is reviewed as 5-hydroxytryptamine receptor 6 (UniProt P50406); 5-hydroxytryptamine receptor 6 shows late clinical disease relevance led by Alzheimer disease. 3 more disease programs remain visible in the same review block.; 5 linked drugs keep this evidence frame grounded.; the current evidence base includes 133 approved drugs, 6568 compounds, and 880 assays, with lead potency reaching pChEMBL 10.4.

Disease context
Alzheimer disease

5-hydroxytryptamine receptor 6 shows late clinical disease relevance led by Alzheimer disease. 3 more disease programs remain visible in the same review block. 5 linked drugs keep the rationale reviewable. 3 additional disease programs remain visible in the same card. Linked drugs include CERLAPIRDINE, IDALOPIRDINE, INTEPIRDINE.

Start review with Alzheimer disease because it currently carries late clinical support. Linked drugs include CERLAPIRDINE, IDALOPIRDINE, INTEPIRDINE, MASUPIRDINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 5 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 133 approved drugs, 6568 compounds, and 880 assays for this target. The dominant activity type is KI. CHEMBL3329438 is the current potency anchor at pChEMBL 10.4.

Use CHEMBL3329438 as the tractability anchor when discussing potency (pChEMBL 10.4).

Activity source · ChEMBL 36 via Core Engine
133 approved pChEMBL 10.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why 5-hydroxytryptamine receptor 6 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P50406, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Alzheimer disease is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

6568
Total Compounds
880
Total Assays
133
Approved Drugs
IC50: 1868.0, KI: 5911.0, EC50: 156.0, KD: 84.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3329438
 10.4 Ki —
No preferred name
CHEMBL1084794
 10.3 Ki —
No preferred name
CHEMBL3692995
 10.3 Ki —
No preferred name
CHEMBL3785512
 10.3 Kd —
No preferred name
CHEMBL1085462
 10.2 Ki —

Approved Drugs

Structure Compound First Approval
BREXPIPRAZOLE
CHEMBL2105760
 2015
VILAZODONE HYDROCHLORIDE
CHEMBL1615374
 2011
ASENAPINE
CHEMBL3187365
 2009
RASAGILINE
CHEMBL887
 2005
ARIPIPRAZOLE
CHEMBL1112
 2002
ESCITALOPRAM
CHEMBL1508
 2002
TEGASEROD MALEATE
CHEMBL1516474
 2002
DESLORATADINE
CHEMBL1172
 2001
ZIPRASIDONE
CHEMBL708
 2001
KETOTIFEN
CHEMBL534
 1999
KETOTIFEN FUMARATE
CHEMBL1633
 1999
RALOXIFENE
CHEMBL81
 1997
SERTINDOLE
CHEMBL12713
 1996
OLANZAPINE
CHEMBL715
 1996
CARVEDILOL
CHEMBL723
 1995
RISPERIDONE
CHEMBL85
 1993
PAROXETINE
CHEMBL490
 1992
PROPAFENONE
CHEMBL631
 1989
CLOMIPRAMINE
CHEMBL415
 1989
CLOZAPINE
CHEMBL42
 1989
PERGOLIDE
CHEMBL531
 1988
FLUOXETINE
CHEMBL41
 1987
OXYMETAZOLINE
CHEMBL762
 1986
TERFENADINE
CHEMBL17157
 1985
PIMOZIDE
CHEMBL1423
 1984
MAPROTILINE
CHEMBL21731
 1980
AMOXAPINE
CHEMBL1113
 1980
DAPSONE
CHEMBL1043
 1979
BROMOCRIPTINE
CHEMBL493
 1978
CLEMASTINE
CHEMBL1626
 1977
LOXAPINE
CHEMBL831
 1975
MITOTANE
CHEMBL1670
 1970
DOXEPIN
CHEMBL1628227
 1969
CHLORPROTHIXENE
CHEMBL908
 1967
PROPRANOLOL HYDROCHLORIDE
CHEMBL1671
 1967
NORTRIPTYLINE
CHEMBL445
 1964
METHYSERGIDE
CHEMBL1065
 1962
THIORIDAZINE
CHEMBL479
 1962
CYPROHEPTADINE
CHEMBL516
 1961
AMITRIPTYLINE
CHEMBL629
 1961
FLUPHENAZINE
CHEMBL726
 1959
ORPHENADRINE
CHEMBL900
 1957
CHLORPROMAZINE
CHEMBL71
 1957
PROMAZINE
CHEMBL564
 1956
PROCHLORPERAZINE
CHEMBL728
 1956
ERGOTAMINE
CHEMBL442
 1948
DIHYDROERGOTAMINE
CHEMBL1732
 1946
METHYLERGONOVINE
CHEMBL1201356
 1946
DIHYDROERGOTAMINE MESYLATE
CHEMBL1200517
 1946
MEPAZINE
CHEMBL395110
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:07Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3371